Doxil and Gemcitabine in Recurrent Ovarian Cancer

Stopped early · Phase 2

Conditions studied: Ovarian Carcinoma

In brief

Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.

Key facts

Study ID

NCT00312650

Run by

Women and Infants Hospital of Rhode Island

People needed

24

Starts

2006-04-01

Expected to finish

2006-05-01

Last updated by the study team

2015-01-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• recurrent platinum resistant ovarian cancer
• measurable disease

You may not qualify if…

• prior treatment with Doxil or Gemzar
• life expectancy <3months
• cardiac ejection fraction <50%

Where it is running

• Women and Infants' Hospital — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.